Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Brigham and Women's Hospital · Harvard University · +22 more institutions
Abstract
The PARAGON-HF trial randomized 4796 patients with heart failure (HF) and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition.
About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥.5). Among patients who were not obese (BMI
Citation impact
- FWCI
- 92.33
- Percentile
- 100%
- References
- 101
Authors
18- APAlexander PeikertCorresponding
Brigham and Women's Hospital, Harvard University, Medical University of Graz
- MVMuthiah Vaduganathan
Brigham and Women's Hospital, Harvard University
- BCBrian Claggett
Brigham and Women's Hospital, Harvard University
- IJIan J. Kulac
Brigham and Women's Hospital, Harvard University
- SESheldon E. Litwin
Medical University of South Carolina, Ralph H. Johnson VA Medical Center
Topics & keywords
- Medicine
- Ejection fraction
- Heart failure
- Internal medicine
- Cardiology
- Good health and well-being